Canopy Growth Corporation (CGC)
USD 2.83
(-7.21%)
USD 2.83
(-7.21%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -312.82 Million CAD | -105.04% |
| 2022 | -2.84 Billion USD | 862.14% |
| 2021 | -459.32 Million CAD | -233.93% |
| 2020 | -703.21 Million CAD | 112.63% |
| 2019 | -1.66 Billion CAD | -180.81% |
| 2018 | -567.14 Million CAD | -422.91% |
| 2017 | -92.43 Million CAD | -1453.32% |
| 2016 | -692 Thousand CAD | 165.35% |
| 2015 | 938 Thousand CAD | 136.35% |
| 2014 | -7.08 Million CAD | -664.63% |
| 2013 | -925.98 Thousand CAD | -1333.24% |
| 2012 | -64.6 Thousand CAD | -147.01% |
| 2011 | -26.15 Thousand CAD | -8.68% |
| 2010 | -24.06 Thousand CAD | 10.59% |
| 2009 | -26.91 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -7.51 Million USD | -42.61% |
| 2023 Q3 | -11.01 Million USD | -57.17% |
| 2023 FY | - USD | -105.04% |
| 2023 Q1 | -51.72 Million USD | -122.86% |
| 2023 Q2 | -7 Million USD | 86.45% |
| 2023 Q4 | -16.61 Million USD | -50.82% |
| 2022 Q3 | -88.64 Million CAD | -33.06% |
| 2022 FY | - USD | 862.14% |
| 2022 Q1 | 1.63 Billion CAD | 3561.9% |
| 2022 Q4 | 226.32 Million USD | 355.32% |
| 2022 Q2 | -66.61 Million CAD | -104.06% |
| 2021 Q1 | 138.67 Million CAD | 270.02% |
| 2021 Q2 | -210.33 Million CAD | -251.67% |
| 2021 Q3 | -21.51 Million CAD | 89.77% |
| 2021 Q4 | -47.36 Million CAD | -120.12% |
| 2021 FY | - CAD | -233.93% |
| 2020 Q2 | -2.04 Million CAD | 98.82% |
| 2020 Q3 | -479.18 Million CAD | -23286.48% |
| 2020 Q4 | -81.56 Million CAD | 82.98% |
| 2020 Q1 | -173.17 Million CAD | 91.74% |
| 2020 FY | - CAD | 112.63% |
| 2019 Q2 | -73.72 Million CAD | -63.99% |
| 2019 Q1 | -44.95 Million CAD | 63.61% |
| 2019 Q4 | -2.09 Billion CAD | -1491.7% |
| 2019 FY | - CAD | -180.81% |
| 2019 Q3 | -131.66 Million CAD | -78.6% |
| 2018 FY | - CAD | -422.91% |
| 2018 Q1 | -30.16 Million CAD | 25.31% |
| 2018 Q2 | -198.83 Million CAD | -559.27% |
| 2018 Q3 | -140.31 Million CAD | 29.43% |
| 2018 Q4 | -123.54 Million CAD | 11.95% |
| 2017 FY | - CAD | -1453.32% |
| 2017 Q4 | -40.38 Million CAD | 36.85% |
| 2017 Q3 | -63.93 Million CAD | -1184.08% |
| 2017 Q2 | 5.89 Million CAD | 136.96% |
| 2017 Q1 | 2.48 Million CAD | 130.77% |
| 2016 FY | - CAD | 165.35% |
| 2016 Q4 | -8.08 Million CAD | -185.49% |
| 2016 Q2 | 8.4 Million CAD | 385.36% |
| 2016 Q1 | -2.94 Million CAD | 29.9% |
| 2016 Q3 | 9.46 Million CAD | 12.63% |
| 2015 Q4 | -4.2 Million CAD | -257.45% |
| 2015 FY | - CAD | 136.35% |
| 2015 Q3 | -1.17 Million CAD | -117.55% |
| 2015 Q2 | 6.69 Million CAD | 431.02% |
| 2015 Q1 | 1.26 Million CAD | 889.93% |
| 2014 Q1 | -1.12 Million CAD | 5.6% |
| 2014 FY | - CAD | -664.63% |
| 2014 Q4 | -159.6 Thousand CAD | 93.57% |
| 2014 Q3 | -2.48 Million CAD | -8.66% |
| 2014 Q2 | -2.28 Million CAD | -103.37% |
| 2013 Q2 | -7269.00 CAD | 80.75% |
| 2013 Q3 | -28.19 Thousand CAD | -287.92% |
| 2013 FY | - CAD | -1333.24% |
| 2013 Q4 | -1.18 Million CAD | -4118.78% |
| 2013 Q1 | -37.75 Thousand CAD | -667.75% |
| 2012 Q4 | -4918.00 CAD | 58.76% |
| 2012 Q1 | -3627.00 CAD | 58.33% |
| 2012 Q2 | -22.07 Thousand CAD | -508.66% |
| 2012 Q3 | -11.92 Thousand CAD | 45.98% |
| 2012 FY | - CAD | -147.01% |
| 2011 Q4 | -8705.00 CAD | 3.11% |
| 2011 Q3 | -8984.00 CAD | -273.09% |
| 2011 Q1 | -377.00 CAD | 95.01% |
| 2011 FY | - CAD | -8.68% |
| 2011 Q2 | -2408.00 CAD | -538.73% |
| 2010 Q4 | -7548.00 CAD | 43.0% |
| 2010 Q3 | -13.24 Thousand CAD | -283.97% |
| 2010 Q2 | -3449.00 CAD | -2399.28% |
| 2010 Q1 | -138.00 CAD | 98.43% |
| 2010 FY | - CAD | 10.59% |
| 2009 FY | - CAD | 0.0% |
| 2009 Q2 | - CAD | 0.0% |
| 2009 Q3 | -18 Thousand CAD | 0.0% |
| 2009 Q4 | -8777.00 CAD | 51.25% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Theratechnologies Inc. | -10.31 Million USD | -2933.386% |
| Harrow Health, Inc. | 9.72 Million USD | 3317.392% |
| Dynavax Technologies Corporation | 9.66 Million USD | 3336.365% |
| Biofrontera Inc. | -18.45 Million USD | -1595.264% |
| Cronos Group Inc. | -72.14 Million USD | -333.585% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -6813.304% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 66.176% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -766.989% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 1290.99% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -43907.456% |
| Radius Health, Inc. | 38.31 Million USD | 916.567% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -9630.024% |
| DURECT Corporation | -24.68 Million USD | -1167.327% |
| ProPhase Labs, Inc. | -14.82 Million USD | -2009.847% |
| Safety Shot Inc | -12.18 Million USD | -2467.274% |
| Phibro Animal Health Corporation | 84.6 Million USD | 469.741% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -13206.068% |
| Alvotech | -484.86 Million USD | 35.481% |
| Assertio Holdings, Inc. | -222.44 Million USD | -40.63% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 418.36% |
| Rockwell Medical, Inc. | -4.69 Million USD | -6564.401% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -8079.728% |
| Procaps Group S.A. | 104.02 Million USD | 400.717% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | -96.929% |
| SCYNEXIS, Inc. | 73.47 Million USD | 525.737% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -30811.759% |
| Viatris Inc. | 3.51 Billion USD | 108.896% |
| OptiNose, Inc. | -15.55 Million USD | -1911.361% |
| SIGA Technologies, Inc. | 84.15 Million USD | 471.707% |
| Tilray Brands, Inc. | -72.84 Million USD | -329.454% |
| PetIQ, Inc. | 81.48 Million USD | 483.903% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -8079.728% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 175.181% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -7875.491% |
| Alimera Sciences, Inc. | 7.27 Million USD | 4399.437% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 201.459% |
| Silver Spike Investment Corp. | 7.34 Million USD | 4361.884% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -7739.001% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 968.216% |
| Journey Medical Corporation | 1.92 Million USD | 16384.591% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -7327.269% |
| Alpha Teknova, Inc. | -25.53 Million USD | -1124.899% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -1761.622% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 38625.493% |
| PainReform Ltd. | -9.56 Million USD | -3169.171% |
| Cosmos Health Inc. | -17.06 Million USD | -1733.494% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | -109.775% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -3623.688% |
| Embecta Corp. | 245.4 Million USD | 227.476% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -8547.296% |
| Talphera, Inc. | -9.84 Million USD | -3078.49% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 292.04% |
| Incannex Healthcare Limited | -18.5 Million USD | -1590.591% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -1461.731% |
| Shineco, Inc. | -26.55 Million USD | -1078.082% |
| Procaps Group, S.A. | 104.02 Million USD | 400.717% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 386.157% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 26565.905% |
| Lantheus Holdings, Inc. | 491 Million USD | 163.712% |
| Alvotech | -484.86 Million USD | 35.481% |
| Hempacco Co., Inc. | -12.77 Million USD | -2349.075% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 503.637% |
| Bright Green Corporation | - USD | Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -108.401% |
| Kamada Ltd. | 21.53 Million USD | 1552.712% |
| Indivior PLC | 66 Million USD | 573.98% |
| Evoke Pharma, Inc. | -7.29 Million USD | -4189.829% |
| Flora Growth Corp. | -45.87 Million USD | -581.986% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | -1461.731% |
| Evolus, Inc. | -41.81 Million USD | -648.211% |
| HUTCHMED (China) Limited | 25.52 Million USD | 1325.427% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 229.554% |
| Akanda Corp. | -27.73 Million USD | -1027.886% |